Landmark Non-inferiority Clinical Trial Demonstrates Nanodropper’s Positive Impact on Glaucoma Treatment
Nanodropper, Inc., an ophthalmic device company that created the eyedrop volume-reducing Nanodropper® Adaptor, announced today that its clinical trial “An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper” was published in the journal Ophthalmology. This was a…
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
PolyActiva is a Melbourne-based ophthalmology company developing a novel proprietary drug delivery platform. Today the company reported promising interim results from an ongoing Phase 2a clinical study for its PA5108 Ocular Implant in subjects with mild to moderate glaucoma. This ocular implant is…
